Systemic lidocaine in pain due to peripheral nerve injury and predictors of response
To investigate the effects of IV lidocaine on spontaneous and evoked pain (allodynia and hyperalgesia) due to peripheral nerve injury (postherpetic neuralgia or nerve trauma) using quantitative sensory testing. The authors randomized 22 patients to receive lidocaine 5 mg/kg IV during 30 minutes or p...
Gespeichert in:
| Veröffentlicht in: | Neurology 2004-01, Vol.62 (2), p.218-225 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 225 |
|---|---|
| container_issue | 2 |
| container_start_page | 218 |
| container_title | Neurology |
| container_volume | 62 |
| creator | ATTAL, N ROUAUD, J BRASSEUR, L CHAUVIN, M BOUHASSIRA, D |
| description | To investigate the effects of IV lidocaine on spontaneous and evoked pain (allodynia and hyperalgesia) due to peripheral nerve injury (postherpetic neuralgia or nerve trauma) using quantitative sensory testing.
The authors randomized 22 patients to receive lidocaine 5 mg/kg IV during 30 minutes or placebo in a double-blind crossover design and 16 patients subsequently received mexiletine on an open basis titrated from 400 to 1,000 mg per day (mean 737 mg/day).
Lidocaine induced a significant decrease in ongoing pain for up to 6 hours with a peak effect 60 to 120 minutes postinjection. The drug also decreased mechanical dynamic allodynia and static (punctate) mechanical allodynia/hyperalgesia, but not thermal allodynia and hyperalgesia. The effects of lidocaine and mexiletine on spontaneous pain intensity were significantly higher in patients with concomitant mechanical allodynia in comparison with those without allodynia.
These data indicate modality-specific antihyperalgesic effects of IV lidocaine in patients with peripheral nerve injury. Patients with mechanical allodynia may be good candidates for treatment with local anesthetic-like drugs and possibly with other sodium-channel blockers. |
| doi_str_mv | 10.1212/01.wnl.0000103237.62009.77 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80123666</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80123666</sourcerecordid><originalsourceid>FETCH-LOGICAL-c493t-67a7832d89e049d1f6c6712654cc04ca962ecc9c5e7cd46f28545764f03695d3</originalsourceid><addsrcrecordid>eNpFkE1Lw0AQhhdRtFb_giyC3hL3exNvUvyCogcLelvW3QluSZO4myj996a20LnMwDzvDDwIXVKSU0bZDaH5b1PnZCxKOOM6V4yQMtf6AE2oZCpTnH0cogkhrMh4oYsTdJrScsQl0-UxOqFCC0mknqDF2zr1sAoO18G3zoYGcGhwNw7YD4D7FncQQ_cF0da4gfiz2S-HuMa28biL4IPr25hwW-EIqWubBGfoqLJ1gvNdn6LFw_1i9pTNXx-fZ3fzzImS95nSVhec-aIEIkpPK-WUpkxJ4RwRzpaKgXOlk6CdF6pihRRSK1ERrkrp-RRdb892sf0eIPVmFZKDurYNtEMyBaGMK6VG8HYLutimFKEyXQwrG9eGErNRagg17y9zs1dq_pUarcfwxe7L8LkCv4_uHI7A1Q6wydm6irZxIe05KZhgkvM_iDR_2Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80123666</pqid></control><display><type>article</type><title>Systemic lidocaine in pain due to peripheral nerve injury and predictors of response</title><source>MEDLINE</source><source>Journals@Ovid Ovid Autoload</source><source>Alma/SFX Local Collection</source><creator>ATTAL, N ; ROUAUD, J ; BRASSEUR, L ; CHAUVIN, M ; BOUHASSIRA, D</creator><creatorcontrib>ATTAL, N ; ROUAUD, J ; BRASSEUR, L ; CHAUVIN, M ; BOUHASSIRA, D</creatorcontrib><description>To investigate the effects of IV lidocaine on spontaneous and evoked pain (allodynia and hyperalgesia) due to peripheral nerve injury (postherpetic neuralgia or nerve trauma) using quantitative sensory testing.
The authors randomized 22 patients to receive lidocaine 5 mg/kg IV during 30 minutes or placebo in a double-blind crossover design and 16 patients subsequently received mexiletine on an open basis titrated from 400 to 1,000 mg per day (mean 737 mg/day).
Lidocaine induced a significant decrease in ongoing pain for up to 6 hours with a peak effect 60 to 120 minutes postinjection. The drug also decreased mechanical dynamic allodynia and static (punctate) mechanical allodynia/hyperalgesia, but not thermal allodynia and hyperalgesia. The effects of lidocaine and mexiletine on spontaneous pain intensity were significantly higher in patients with concomitant mechanical allodynia in comparison with those without allodynia.
These data indicate modality-specific antihyperalgesic effects of IV lidocaine in patients with peripheral nerve injury. Patients with mechanical allodynia may be good candidates for treatment with local anesthetic-like drugs and possibly with other sodium-channel blockers.</description><identifier>ISSN: 0028-3878</identifier><identifier>EISSN: 1526-632X</identifier><identifier>DOI: 10.1212/01.wnl.0000103237.62009.77</identifier><identifier>PMID: 14745057</identifier><identifier>CODEN: NEURAI</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Adult ; Aged ; Analgesics - administration & dosage ; Analgesics - therapeutic use ; Biological and medical sciences ; Cold Temperature ; Cross-Over Studies ; Double-Blind Method ; Female ; Hot Temperature ; Humans ; Hyperalgesia - drug therapy ; Hyperalgesia - etiology ; Infusions, Intravenous ; Lidocaine - administration & dosage ; Lidocaine - therapeutic use ; Male ; Medical sciences ; Mexiletine - therapeutic use ; Middle Aged ; Neuralgia - drug therapy ; Neuralgia - etiology ; Neurology ; Pain - drug therapy ; Pain - etiology ; Pain Threshold - drug effects ; Peripheral Nerve Injuries ; Physical Stimulation ; Sensory Thresholds - drug effects ; Touch ; Treatment Outcome</subject><ispartof>Neurology, 2004-01, Vol.62 (2), p.218-225</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c493t-67a7832d89e049d1f6c6712654cc04ca962ecc9c5e7cd46f28545764f03695d3</citedby><cites>FETCH-LOGICAL-c493t-67a7832d89e049d1f6c6712654cc04ca962ecc9c5e7cd46f28545764f03695d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15424253$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14745057$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ATTAL, N</creatorcontrib><creatorcontrib>ROUAUD, J</creatorcontrib><creatorcontrib>BRASSEUR, L</creatorcontrib><creatorcontrib>CHAUVIN, M</creatorcontrib><creatorcontrib>BOUHASSIRA, D</creatorcontrib><title>Systemic lidocaine in pain due to peripheral nerve injury and predictors of response</title><title>Neurology</title><addtitle>Neurology</addtitle><description>To investigate the effects of IV lidocaine on spontaneous and evoked pain (allodynia and hyperalgesia) due to peripheral nerve injury (postherpetic neuralgia or nerve trauma) using quantitative sensory testing.
The authors randomized 22 patients to receive lidocaine 5 mg/kg IV during 30 minutes or placebo in a double-blind crossover design and 16 patients subsequently received mexiletine on an open basis titrated from 400 to 1,000 mg per day (mean 737 mg/day).
Lidocaine induced a significant decrease in ongoing pain for up to 6 hours with a peak effect 60 to 120 minutes postinjection. The drug also decreased mechanical dynamic allodynia and static (punctate) mechanical allodynia/hyperalgesia, but not thermal allodynia and hyperalgesia. The effects of lidocaine and mexiletine on spontaneous pain intensity were significantly higher in patients with concomitant mechanical allodynia in comparison with those without allodynia.
These data indicate modality-specific antihyperalgesic effects of IV lidocaine in patients with peripheral nerve injury. Patients with mechanical allodynia may be good candidates for treatment with local anesthetic-like drugs and possibly with other sodium-channel blockers.</description><subject>Adult</subject><subject>Aged</subject><subject>Analgesics - administration & dosage</subject><subject>Analgesics - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cold Temperature</subject><subject>Cross-Over Studies</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Hot Temperature</subject><subject>Humans</subject><subject>Hyperalgesia - drug therapy</subject><subject>Hyperalgesia - etiology</subject><subject>Infusions, Intravenous</subject><subject>Lidocaine - administration & dosage</subject><subject>Lidocaine - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mexiletine - therapeutic use</subject><subject>Middle Aged</subject><subject>Neuralgia - drug therapy</subject><subject>Neuralgia - etiology</subject><subject>Neurology</subject><subject>Pain - drug therapy</subject><subject>Pain - etiology</subject><subject>Pain Threshold - drug effects</subject><subject>Peripheral Nerve Injuries</subject><subject>Physical Stimulation</subject><subject>Sensory Thresholds - drug effects</subject><subject>Touch</subject><subject>Treatment Outcome</subject><issn>0028-3878</issn><issn>1526-632X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1Lw0AQhhdRtFb_giyC3hL3exNvUvyCogcLelvW3QluSZO4myj996a20LnMwDzvDDwIXVKSU0bZDaH5b1PnZCxKOOM6V4yQMtf6AE2oZCpTnH0cogkhrMh4oYsTdJrScsQl0-UxOqFCC0mknqDF2zr1sAoO18G3zoYGcGhwNw7YD4D7FncQQ_cF0da4gfiz2S-HuMa28biL4IPr25hwW-EIqWubBGfoqLJ1gvNdn6LFw_1i9pTNXx-fZ3fzzImS95nSVhec-aIEIkpPK-WUpkxJ4RwRzpaKgXOlk6CdF6pihRRSK1ERrkrp-RRdb892sf0eIPVmFZKDurYNtEMyBaGMK6VG8HYLutimFKEyXQwrG9eGErNRagg17y9zs1dq_pUarcfwxe7L8LkCv4_uHI7A1Q6wydm6irZxIe05KZhgkvM_iDR_2Q</recordid><startdate>20040127</startdate><enddate>20040127</enddate><creator>ATTAL, N</creator><creator>ROUAUD, J</creator><creator>BRASSEUR, L</creator><creator>CHAUVIN, M</creator><creator>BOUHASSIRA, D</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040127</creationdate><title>Systemic lidocaine in pain due to peripheral nerve injury and predictors of response</title><author>ATTAL, N ; ROUAUD, J ; BRASSEUR, L ; CHAUVIN, M ; BOUHASSIRA, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c493t-67a7832d89e049d1f6c6712654cc04ca962ecc9c5e7cd46f28545764f03695d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Analgesics - administration & dosage</topic><topic>Analgesics - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cold Temperature</topic><topic>Cross-Over Studies</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Hot Temperature</topic><topic>Humans</topic><topic>Hyperalgesia - drug therapy</topic><topic>Hyperalgesia - etiology</topic><topic>Infusions, Intravenous</topic><topic>Lidocaine - administration & dosage</topic><topic>Lidocaine - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mexiletine - therapeutic use</topic><topic>Middle Aged</topic><topic>Neuralgia - drug therapy</topic><topic>Neuralgia - etiology</topic><topic>Neurology</topic><topic>Pain - drug therapy</topic><topic>Pain - etiology</topic><topic>Pain Threshold - drug effects</topic><topic>Peripheral Nerve Injuries</topic><topic>Physical Stimulation</topic><topic>Sensory Thresholds - drug effects</topic><topic>Touch</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ATTAL, N</creatorcontrib><creatorcontrib>ROUAUD, J</creatorcontrib><creatorcontrib>BRASSEUR, L</creatorcontrib><creatorcontrib>CHAUVIN, M</creatorcontrib><creatorcontrib>BOUHASSIRA, D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ATTAL, N</au><au>ROUAUD, J</au><au>BRASSEUR, L</au><au>CHAUVIN, M</au><au>BOUHASSIRA, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Systemic lidocaine in pain due to peripheral nerve injury and predictors of response</atitle><jtitle>Neurology</jtitle><addtitle>Neurology</addtitle><date>2004-01-27</date><risdate>2004</risdate><volume>62</volume><issue>2</issue><spage>218</spage><epage>225</epage><pages>218-225</pages><issn>0028-3878</issn><eissn>1526-632X</eissn><coden>NEURAI</coden><abstract>To investigate the effects of IV lidocaine on spontaneous and evoked pain (allodynia and hyperalgesia) due to peripheral nerve injury (postherpetic neuralgia or nerve trauma) using quantitative sensory testing.
The authors randomized 22 patients to receive lidocaine 5 mg/kg IV during 30 minutes or placebo in a double-blind crossover design and 16 patients subsequently received mexiletine on an open basis titrated from 400 to 1,000 mg per day (mean 737 mg/day).
Lidocaine induced a significant decrease in ongoing pain for up to 6 hours with a peak effect 60 to 120 minutes postinjection. The drug also decreased mechanical dynamic allodynia and static (punctate) mechanical allodynia/hyperalgesia, but not thermal allodynia and hyperalgesia. The effects of lidocaine and mexiletine on spontaneous pain intensity were significantly higher in patients with concomitant mechanical allodynia in comparison with those without allodynia.
These data indicate modality-specific antihyperalgesic effects of IV lidocaine in patients with peripheral nerve injury. Patients with mechanical allodynia may be good candidates for treatment with local anesthetic-like drugs and possibly with other sodium-channel blockers.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>14745057</pmid><doi>10.1212/01.wnl.0000103237.62009.77</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-3878 |
| ispartof | Neurology, 2004-01, Vol.62 (2), p.218-225 |
| issn | 0028-3878 1526-632X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80123666 |
| source | MEDLINE; Journals@Ovid Ovid Autoload; Alma/SFX Local Collection |
| subjects | Adult Aged Analgesics - administration & dosage Analgesics - therapeutic use Biological and medical sciences Cold Temperature Cross-Over Studies Double-Blind Method Female Hot Temperature Humans Hyperalgesia - drug therapy Hyperalgesia - etiology Infusions, Intravenous Lidocaine - administration & dosage Lidocaine - therapeutic use Male Medical sciences Mexiletine - therapeutic use Middle Aged Neuralgia - drug therapy Neuralgia - etiology Neurology Pain - drug therapy Pain - etiology Pain Threshold - drug effects Peripheral Nerve Injuries Physical Stimulation Sensory Thresholds - drug effects Touch Treatment Outcome |
| title | Systemic lidocaine in pain due to peripheral nerve injury and predictors of response |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T08%3A32%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Systemic%20lidocaine%20in%20pain%20due%20to%20peripheral%20nerve%20injury%20and%20predictors%20of%20response&rft.jtitle=Neurology&rft.au=ATTAL,%20N&rft.date=2004-01-27&rft.volume=62&rft.issue=2&rft.spage=218&rft.epage=225&rft.pages=218-225&rft.issn=0028-3878&rft.eissn=1526-632X&rft.coden=NEURAI&rft_id=info:doi/10.1212/01.wnl.0000103237.62009.77&rft_dat=%3Cproquest_cross%3E80123666%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80123666&rft_id=info:pmid/14745057&rfr_iscdi=true |